Homepage Top Section2

The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. It makes the combination the first regimen that pairs a programmed death-1 (PD-1)

The partnership will combine Combotope’s SMART-Phage discovery platform with Boehringer Ingelheim’s research and development capabilities, focusing on multiple identified oncology targets. Combotope CEO Ola Blixt said: “At Combotope,

This expands intellectual property protection already in place for Genprex in jurisdictions such as China, Europe, Japan, Russia and the US. Genprex’s Reqorsa is currently in development alongside

According to a regulatory filing, Sun Pharma will buy the entire issued and outstanding share capital of Innovcare Lifesciences via a cash transaction. The company expects to close

The partnership will bring together Voro Therapeutics’ tumour-activated biologics platform with Alloy Therapeutics’ cluster of differentiation 3 (CD3) antibodies and multispecific engineering capabilities. This joint effort aims to

The collaboration involves up to $56m in upfront payments to AbCellera for the first two research programmes, with an additional $28m payable if a third programme begins within

The agreement broadens AviadoBio’s existing rights, which were previously limited to the development of gene therapies for neurological diseases under a 2020 agreement. The vMiX platform leverages adeno-associated

The FDA granted the status to alixorexton for idiopathic hypersomnia while the EC approved the designation for narcolepsy. In the US, the ODD offers incentives such as tax

Under the deal, Simcere will provide funding for exploratory research on a first-in-class novel molecule in the respiratory field. If the research is successful, Simcere will have the